Treatment of posttraumatic stress disorder: Focus on pharmacotherapy

Megan Ehret, PharmD, MS, BCPP

How to cite: Ehret M. Treatment of posttraumatic stress disorder: Focus on pharmacotherapy. Ment Health Clin [Internet]. 2019;9(6):373-82. DOI: 10.9740/mhc.2019.11.373.

Abstract

Current clinical practice guidelines for the treatment of posttraumatic stress disorder offer varying recommendations regarding the use of pharmacotherapy. Many direct head-to-head comparisons of pharmacotherapy are lacking, and recommendations are based on meta-analyses and small trials. While selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors are considered first-line pharmacotherapy, clear distinctions do not exist when considering other classes of psychotropic medications. Ultimately, when selecting an appropriate medication for a patient diagnosed with posttraumatic stress disorder, the clinician needs to consider the current symptomatology being experienced, comorbid conditions, and evidence for efficacy of specific treatments prior to initiating medications.

Keywords: posttraumatic stress disorder (PTSD), antidepressants, benzodiazepines, mood stabilizers, antipsychotics, prazosin, anxiety, nightmares

Introduction

Posttraumatic stress disorder (PTSD) can be diagnosed when symptoms have persisted for more than 1 month after exposure to a traumatic event (ie, directly witnessing the traumatic event, witnessing in person the event(s) as it occurred to others, learning that the traumatic event(s) occurred to a close family member or close friend, or experiencing repeated or extreme exposure to aversive details of a traumatic event). Of note, in cases of actual or threatened death of a family member or friend, the event(s) must have been violent or accidental. The core symptoms of PTSD (ie, intrusion, avoidance, negative alterations in cognition and mood, and marked alterations in arousal and reactivity) also must cause significant distress or impairment in social, occupational, or other important areas of functioning. PTSD disorder can occur alone or with other co-occurring Diagnostic and Statistical Manual, 5th edition (DSM-5) disorders, such as substance use disorder, mood disorder, or anxiety disorder. Additionally, PTSD is strongly associated with functional difficulties, reduced quality of life, and adverse physical health outcomes.

The Wave 3 National Epidemiologic Survey on Alcohol and Related Conditions study, using DSM-5 criteria, suggests comparable lifetime (6.1%) and current (4.7%) PTSD prevalence estimates. Estimates of PTSD in active duty US service members ranges from 4% to 17% in those
**Take Home Points**

1. Clinical controversy exists regarding the place of pharmacotherapy in the treatment of posttraumatic stress disorder (PTSD). While some guideline authors consider pharmacotherapy a first-line treatment option, others recommend psychotherapy prior to considering any pharmacotherapy. When pharmacotherapy is chosen, selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors (specifically sertraline, fluoxetine, paroxetine, and venlafaxine) are considered first-line treatment options. Use of antipsychotics and mood stabilizers should be reserved as last-line options.

2. Current guidelines vary on recommendations regarding the role of prazosin for treatment of PTSD nightmares. While older guidelines recommended prazosin based on smaller positive trials, a recent large Veterans Affairs Cooperative Study with negative results had conflicting results regarding the efficacy of the medication. Prazosin continues to be used clinically in patients who experience a positive response from the medication.

3. Benzodiazepines continue to be contraindicated for the treatment of PTSD, even though up to 74% of patients with a diagnosis of PTSD continue to receive prescriptions for them. Benzodiazepines may actually interfere with the extinction of fear conditioning and/or potentiate the acquisition of fear response and worsen recovery from trauma. Careful consideration should be given prior to use of benzodiazepines for the treatment of PTSD or anxiety associated with PTSD.

Current first-line treatments for PTSD vary even with recent guideline updates. Contradictory recommendations exist between the use of pharmacotherapy or psychotherapy as first-line treatment options. The American Psychiatric Association and British Association of Psychopharmacology guidelines recommend pharmacotherapy and psychotherapy as first-line treatments (Table 1). Conversely, the updated Veterans Affairs/Department of Defense (VA/DoD) and the National Institute for Clinical Excellence assert trauma-focused psychotherapies (TFPs) as superior to pharmacotherapy. They further recommend TFPs as first-line treatment over pharmacotherapy when they are available and preferred by patients.

Recommendations for TFPs (eg, prolonged exposure, narrative exposure therapy, and cognitive processing therapy) mirror the current state of research into PTSD treatment. Two meta-analyses compared the treatment effects of psychotherapies and pharmacotherapies, and the results strongly demonstrate that TFPs have greater change with regard to core PTSD symptoms over pharmacotherapies. Additionally, improvements from TFPs persist longer with fewer negative effects associated with TFPs compared with pharmacotherapy. The positive effects of pharmacotherapy treatments can diminish over time and could be lost when medications are stopped.

Despite current treatment guideline recommendations for psychotherapy as first-line, pharmacotherapies are still used frequently as first-line in the treatment of PTSD. Currently only 2 medications are approved by the US Food and Drug Administration for the treatment of PTSD: paroxetine and sertraline. Polypharmacy and off-label use of medications are extremely common and likely to be driven by the suboptimal response and high prevalence of psychiatric comorbidities. In this article, 3 cases will explore the impact of psychotropic medications on the treatment of PTSD, specifically reviewing the role of antidepressant, mood stabilizer, and antipsychotic medications, the use of prazosin for nightmares associated with PTSD, and the use of benzodiazepines for comorbid anxiety with PTSD.

**Case 1**

A 52-year-old patient presents to the behavioral health clinic complaining of symptoms of anxiety about Veterans Day activities. The patient is a teacher and becomes anxious and easily startled while walking down the hallway at the school. Its crowded space brings back memories of work in the military and having to inform families of service member’s deaths. The patient detailed one experience of providing the news to a young woman when the woman’s husband had died and the faces of the widow’s children when they learned of the death. A diagnosis of PTSD is made and a referral for trauma-focused therapy is provided. Because of increased trouble sleeping and recurrent nightmares, the patient is unable to go to work every day.

The patient returns after 2 sessions of TFP and states an inability to tolerate the therapy and would prefer to trial a medication for PTSD instead. Current medications include lisinopril, atorvastatin, metformin, and levothyroxine.

While TFPs should be recommended first-line for the treatment of PTSD, patients may not be able to tolerate the therapy, may be unable to access the level of therapy required, or may request pharmacotherapy instead. In these cases, current treatment guidelines recommend pharmacotherapy as a treatment option. However,
| Guideline                        | Process                                                       | Intervention Level                                                                 |
|---------------------------------|---------------------------------------------------------------|-------------------------------------------------------------------------------------|
| **APA (2004)**7                 | Systematic review and clinical consensus                      | First Line: Psy, SSRI: fluoxetine, paroxetine, sertraline SNRI: venlafaxine         |
|                                 |                                                               | Second Line: TCA: amitriptyline, desipramine, Nefazodone, Prazosin (combat-related PTSD) |
|                                 |                                                               | Third Line: SGA: risperidone, olanzapine                                           |
| **BAP9 (2014)**                 | Systematic review and expert opinion/clinical experience      | TF: CBT and EMDR, SSRI: paroxetine, sertraline, SNRI: venlafaxine                  |
|                                 |                                                               | Augmentation with: olanzapine, risperidone, prazosin                               |
| **ACPMH10 (2014)**             | Systematic review                                            | TF: CBT or EMDR, SSRI: clinician choice                                             |
|                                 |                                                               | Other antidepressants, Risperidone, Olanzapine, Prazosin                           |
| **ADAC11 (2014)**              | Systematic review and consensus process                      | CBT, SSRI: fluoxetine, paroxetine, sertraline, SNRI: venlafaxine XR, TF: CBT, EMDR |
|                                 |                                                               | Trauma nightmares and improving sleep quality: prazosin                            |
|                                 |                                                               | Medication treatments: venlafaxine, SSRI, antipsychotics                            |
|                                 |                                                               | Amitriptyline, aripiprazole, bupropion SR, buspirone, carbamazepine, desipramine, duloxetine, escitalopram, imipramine, lamotrigine, memantine, quetiapine, risperidone, topiramate, trazodone Adjunctive: clonidine, gabapentin, levetiracetam, pregabaline, quetiapine, tiagabine |
| **VA/DoD12 (2017)**            | Systematic review and weighted recommendations               | TF: Psy or SM, SSRI: paroxetine, sertraline, fluoxetine, SNRI: venlafaxine          |
|                                 |                                                               | Non-TF Psy, SSRI: paroxetine, sertraline, fluoxetine, SNRI: venlafaxine            |
| **NICE13 (2018)**              | Systematic review and expert testimony, including costs      | TF: CBT, EMDR: non-combat trauma if a preference for EMDR                           |
|                                 |                                                               | TF: computerized CBT: preference versus face-to-face                              |
|                                 |                                                               | CBT for specific symptoms: sleep disturbance or anger                              |
|                                 |                                                               | Medication treatments: venlafaxine, SSRI, antipsychotics                            |
| **AHRO14 (2018)**              | Systematic review and weighted recommendations with peer review and public commentary | CBT (exposure and mixed therapies), SSRI: fluoxetine, paroxetine, SNRI: venlafaxine | CPT, CT, EMDR, and NET | BE Psy, imagery rehearsal therapy, trauma affect regulation |
|                                 |                                                               | Prazosin, Topiramate, Olanzapine, Risperidone, Sertraline                           |
| **APA15 (2017)**               | Systematic review; compared to previous recommendations      | Strongly recommends: TF: Psy interventions: CBT, CPT, CT, PET                       |
|                                 |                                                               | Suggests or conditionally recommends: BE Psy, EMDR, NET Supports: fluoxetine, paroxetine, sertraline, venlafaxine |
|                                 |                                                               | ...                                                                                 |
|                                 |                                                               | ...                                                                                 |

ACPMH = Australian Centre for Posttraumatic Mental Health; ADAC = Anxiety Disorders Association of Canada; AHRO = Agency for Healthcare Research and Quality; APA = American Psychiatric Association; BAP = British Association of Psychopharmacology; BE Psy = brief eclectic psychotherapy; CBT = cognitive behavioral therapy; CPT = cognitive processing therapy; CT = cognitive therapy; EMDR = eye movement desensitization and reprocessing; NET = narrative exposure therapy; NICE = National Institute for Clinical Excellence; PET = prolonged exposure therapy; Psy = psychotherapy; PTSD = posttraumatic stress disorder; SGA = second generation antipsychotic; SM = stress management; SNRI = selective serotonin reuptake inhibitors; SSRI = selective serotonin reuptake inhibitors; TCA = tri-cyclic antidepressant; TF = trauma-focused; VA/DoD = Veterans Association/Department of Defense.
medication recommendations differ across the various guidelines. The majority conclude that selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) are first-line treatments due to their positive effects on re-experiencing, avoidance, and hyperarousal symptoms. Several guidelines recommend specific antidepressants (ie, fluoxetine, paroxetine, sertraline, and venlafaxine) compared to others in the same or similar classes. Results of 4 systematic reviews and meta-analyses are fairly consistent demonstrating greater efficacy of paroxetine, fluoxetine, and venlafaxine compared to placebo as monotherapy for the treatment of PTSD, while 3 studies of the 4 find significance with sertraline as well (Table 2).

Specific antidepressants are recommended in particular guidelines, but whether or not there are meaningful differences in efficacy between SSRIs and SNRIs can be debated. The lack of recommendation for or against a medication in several guidelines was based on available efficacy data and known adverse effects of the medication, while other guidelines include expert opinion as evidence for recommending a medication (Table 1). The lack of robust studies to warrant a recommendation for or against several antidepressants (ie, escitalopram, duloxetine, levomilnacipran, vilazodone, bupropion, mirtazapine, and vortioxetine) leaves the clinician with questions regarding their place in therapy. While a paucity of data for these particular antidepressants exists, clinicians should consider their use after weighing any known adverse effects, comorbid conditions, potential interactions, warnings, and risks when selecting an appropriate antidepressant medication, as one would do in the treatment of major depressive disorder.

The use of citalopram as a first-line agent should be avoided as one meta-analysis found insufficient evidence of efficacy and a lack of separation from placebo in addition to the known QTc prolongation warning. While this recommendation is not a contraindication to the use of citalopram, clinicians are advised to evaluate the patient’s medication regimen and preexisting medical issues prior to selecting citalopram.

Other second- and third-line antidepressants with strong efficacy include nefazodone, imipramine, and phenelzine. Recent research on these agents is lacking, however older placebo-controlled studies demonstrated modest therapeutic effects. Although the confidence in this data can be low, it does demonstrate that nefazodone significantly improves PTSD symptoms in a veteran population. Additionally, when compared to sertraline in two studies, nefazodone demonstrated no difference on outcome measures such as the Clinician Administered PTSD Scale (CAPS). Larger nefazodone trials for the treatment of PTSD were planned, but when the medication received its black box warning for severe and possibly irreversible liver failure in 2002, the trials were canceled. One small study has also demonstrated measurable therapeutic effects of imipramine and phenelzine in combat veterans. In the most recent meta-analysis, phenergan was considered better than many of the other active treatments (ie, imipramine, sertraline, guanfacine, tiagabine, bupropion, prazosin, divalproex, and citalopram) and was the only medication that was significantly better than placebo in terms of dropout rate (odds ratio 7.50, 95% CI 1.72-32.80). Even with positive efficacy data, these medications have fallen out of favor because of their adverse effects. With careful implementation and proper monitoring, the adverse effects (ie, sleep enhancing effects of imipramine or reduced sexual dysfunction from nefazodone) could be used favorably.

The use of antipsychotics for general PTSD symptomatology is controversial and confusing regarding differences in monotherapy versus augmentation strategies, and when comparing results from meta-analyses or recommendations from guidelines. Some authors recommend them as second-line as monotherapy or third-line as augmentation strategies, and others recommend against their use altogether (Table 1). Risperidone has mixed results from meta-analyses with authors reporting benefit in 2 of the 4 applicable publications. Olanzapine showed statistically significant benefit in 1 out of the 4 meta-analyses reported (Table 2). A recent study using quetiapine as monotherapy demonstrated a small to moderate effect size comparing endpoint CAPS total scores between quetiapine and placebo (Cohen d = 0.49), but the study had a high risk of bias including a lack of information regarding the amount of missing data, method of how the missing data was handled, high attrition, and differential dropout (53% dropout for placebo vs 31% dropout for quetiapine).

Risperidone and olanzapine are the only atypical antipsychotics with data on their use as augmenting agents. Meta-analyses concluded small effect sizes and lack of

---

**TABLE 2: Range of effect sizes using CAPS/SPRINT/PSS-I for monoagent pharmacotherapy**

| Drug          | Point Estimate | Range      | No. of Meta-Analyses With Significant Differences |
|---------------|----------------|------------|-----------------------------------------------|
| Fluoxetine    | 0.23-0.43      | 4          |                                               |
| Paroxetine    | 0.36-0.74      | 4          |                                               |
| Venlafaxine   | 0.20-1.78      | 4          |                                               |
| Sertraline    | 0.15-0.51      | 3          |                                               |
| Risperidone   | 0.27-0.48      | 2          |                                               |
| Olanzapine    | −0.10 to 0.72  | 1          |                                               |

CAPS = Clinician-Administered PTSD Scale; SPRINT = Short PTSD Rating Interview; PSS-I = PTSD Symptom Scale-Interview.
clinical significance for both medications. In a VA Cooperative Study \( (N = 2477) \), risperidone augmentation was compared to placebo for treatment of PTSD resistant to SSRIs. After 6 months, no difference in change from baseline CAPS scores was seen. In a subscale analysis, differences in symptoms of reexperiencing and hyperarousal were found to be statistically, but not clinically, significant.

Clinicians need to weigh the small benefit with the risk when considering the use of antipsychotics for the treatment of PTSD and limit them to last-line for general PTSD symptomatology. Risks include adverse effects that may exacerbate a patient’s comorbidities or result in new medical problems such as metabolic syndrome, hyperprolactinemia, or potential extrapyramidal effects.28,29

Mood stabilizers, including topiramate, lamotrigine, and divalproex have contradictory recommendations within the various guidelines. A recent meta-analysis16 did not find a significant effect size for topiramate or lamotrigine, and in a single study30 divalproex monotherapy did not demonstrate efficacy in a small sample of veterans over 8 to 12 weeks of treatment. Adverse effects associated with mood stabilizers could also hinder use. Topiramate is known to cause paresthesia, metabolic acidosis, kidney stones, and cognitive adverse effects, while lamotrigine’s risk of Stevens-Johnson syndrome limits its rapid titration.31,32 Divalproex requires monitoring of liver enzymes and platelets. Additionally, it has significant risks of weight gain, hyperammonemia, polycystic ovarian syndrome, and teratogenicity.33 Similar to antipsychotics, the use of mood stabilizers should be limited to the treatment of other comorbid psychiatric illnesses.

When selecting a pharmacotherapy treatment option for the patient in case 1, the clinician should identify the specific symptoms the patient is experiencing. One should use potential adverse effects (eg, sedation) to benefit target symptoms (eg, insomnia). Additionally, one must recognize potential adverse effects the patient may not be able to tolerate. In the current case, the patient is experiencing anxiety, trouble sleeping, guilt, and distress. Antidepressant medications, in particular SSRIs and SNRIs, would be effective for most of these symptoms. While paroxetine is the most sedating of consistently recommended antidepressants and may be beneficial to the patient, risks of sexual dysfunction and withdrawal should also be discussed. If the patient is able to tolerate the adverse effects and demonstrate adherence, paroxetine would be an ideal recommendation. Other SSRIs including sertraline and fluoxetine could be considered as potential treatment options. SNRIs and fluoxetine may alleviate the anxiety, but they may also contribute to increased insomnia if dosed late in the day. Proper education on adverse effects and proper titration is essential for continued benefit of the medication.

Case 2

A 37-year-old Navy officer presents to the behavioral health clinic complaining of inability to sleep. The psychologist completing the intake discovers a recent event in which the officer was called to help find a fellow officer who did not show up for a class and discovered that the other officer had died by suicide. The Navy officer tried to perform life saving measures but was unsuccessful. When questioned further regarding the inability to sleep, the patient reports frequent awakenings after nightmares of seeing the scene of the suicide. Other symptoms include being on edge at home, feeling trapped and hopeless, and being unable to help with simple tasks at home such as taking care of the children. Driving home each night takes longer due to avoiding the street where the fellow officer lived. When the patient’s phone rings during the intake, the psychologist notes that the officer jumps. The officer explains constant jumping when the phone rings, anticipating a similar call as the one received about the suicide. The psychologist diagnoses the patient with PTSD and brings the case to the team for discussion of treatment options.

The PTSD-associated nightmares are frequently studied because of the high rate of patient reports (up to 80%).34 The presence of nightmares following a traumatic event predicts subsequent onset of PTSD.35 Unfortunately, PTSD-associated nightmares can persist throughout life even if core PTSD symptoms resolve.36 Currently, treatment of nightmares associated with PTSD is a controversial topic. Pharmacotherapy is frequently used without recommendation for the treatment of nightmares associated with PTSD.12

Prazosin is a widely studied and used medication for PTSD-related nightmares. However, debate has recently arisen regarding its continued use for this purpose. Multiple studies7-14 have demonstrated the efficacy of prazosin for the treatment of PTSD-associated nightmares, and many guidelines recommend its use. Contradicting most guidelines, the most recent revision of the VA/DoD PTSD Guidelines32 changed its recommendation for PTSD-related nightmares to state that there is insufficient evidence to recommend for or against the use of prazosin as monotherapy or augmentation therapy. Disagreements between guidelines stem partly from the criteria according to which studies were included in the assessment.37 The VA/DoD recommendations were based on 4 small, published trials38-41 of variable quality. While most of these trials had promising results for nightmares, in a much larger, well-designed VA Cooperative multi-site trial42 \( (N = 304) \), prazosin (mean maintenance dose = 14.8
mg + 6.1 mg) failed to separate from placebo in the treatment of both global symptoms of PTSD and nightmares. At the time of the writing of the VA/DoD guidelines, the VA Cooperative multi-site trial had not been published for the Work Group to review. The Work Group felt it was essential to include the study in the updated recommendations despite its predefined study inclusion criteria because of their knowledge of the study’s data in the public domain. The Work Group had in-depth conversations and debates regarding this recommendation because of: (1) the positive results in nearly all of the small studies, (2) the results of a recent meta-analysis that concluded that prazosin was beneficial at 14 to 27 weeks as an augmentation medication for the global symptoms of PTSD, and (3) the contradictory negative results in the much larger and stronger VA Cooperative Study. In 3 trials (of the 4 smaller trials), prazosin demonstrated a significant decrease in recurrent distressing dreams and improvement in sleep quality, while the VA Cooperative Study demonstrated no difference between prazosin and placebo on recurrent distressing dreams or sleep quality. The Work Group ultimately agreed on not recommending for or against the continuation of prazosin in patients who believe it to be beneficial.

The Work Group concluded that the decision to stop, initiate, or continue prazosin should be individualized based on the history of response and adverse effects experienced. If patients and/or providers decide to discontinue prazosin, a slow taper should be used with monitoring for symptom worsening or reappearance. The Work Group suggests that prazosin may need to be restarted or continued in some patients where response is demonstrated.

While the VA/DoD Work Group did not have the published VA Cooperative Study, the American Academy of Sleep Medicine (AASM) recently released a position paper for the treatment of nightmare disorder in adults, which included a review of the complete, published paper. The position paper recommends image rehearsal therapy for the treatment of PTSD-associated nightmares and nightmare disorder. Additionally, it suggests a host of other options with varied evidence levels, including various psychotherapies and numerous medications, many with very little evidence (eg, nabilone, clonidine, gabapentin).

In addition to the studies reviewed by the VA/DoD Work Group, the AASM reviewed 10 studies (including a retrospective chart review and 4 small, uncontrolled trials) that demonstrated the efficacy of prazosin for the treatment of PTSD-associated nightmares. The Academy notes that it is appropriate to downgrade the recommendation regarding prazosin for this use because of the VA Cooperative Study, but patients may respond well to prazosin and they continue to recommend it as a first-line option.

While much larger than the previous studies, the VA Cooperative Study described several limitations in the full paper. The study enrolled stable patients for treatment, which the principal investigators explained could have resulted in selection bias. Excluding those with psychosocial instability from recruitment because of the concern of suicide and violent behavior resulted in a different population than that previously studied. Similarly, the investigators had concern that enrolling patients who would deteriorate clinically during the 6 months of receiving placebo could have motivated providers to use available open-label prazosin rather than refer patients to this study. The study also did not allow continued use of trazodone, which could have limited those who may have had a response to prazosin. A further limitation is that participants were not screened for sleep apnea or sleep-breathing except by patient history or chart review. This may have interfered with the mechanism of prazosin or masked its possible beneficial effects. With so many different limiting factors and variations from previous studies, many clinicians are uncertain whether prazosin provides efficacy for PTSD-associated nightmares. Given that many clinicians have seen clinical efficacy with the use of prazosin, continuing to use prazosin in patients with no contraindications is appropriate. Patients should be provided proper education regarding the mixed data regarding its efficacy, potential adverse effects, and continued monitoring should be completed.

Risperidone, aripiprazole, and olanzapine are recommended by AASM specifically for PTSD-related nightmares, not general PTSD symptomatology, based on several very small and weak studies. Olanzapine is recommended based on a single case series comparing olanzapine augmentation to different psychotropic treatment regimens in 5 combat veterans. Subjects self-reported the frequency of nightmares. Risperidone is recommended based on 2 studies with self-reported outcomes, a 12-week open label trial evaluating the effects in veterans with chronic PTSD and a retrospective chart review of 10 civilian patients at a regional burn center. A single case series found self-reported substantial improvement but not in total resolution of nightmares with aripiprazole in 4 of the 5 cases. In the recent, placebo-controlled quetiapine study (N = 60), improved sleep was suggested by week 4 of the study (F = 6.22, df = 1.77, P < .05) but the effect was lost over time (F = 1.49, df = 3.117, P = 0.20). These studies have many limitations, and the risks associated with the use of atypical antipsychotics outweigh their potential benefit. Atypical antipsychotics should be reserved as a last-line treatment.
option for PTSD-related nightmares after TFP, antidepressants, and prazosin, but avoided as monotherapy for general PTSD symptomatology because of weak evidence for efficacy.

While benzodiazepines are commonly prescribed for the treatment of PTSD-related insomnia, there is a paucity of evidence to support this practice. Two small trials evaluating the efficacy of alprazolam and clonazepam in reducing symptoms of PTSD, including insomnia and nightmares, via sleep diaries, found no advantage over placebo. Additionally, benzodiazepines and nonbenzodiazepines can increase excitement, irritability, aggression, hostility, and impulsivity. These symptoms can result in attacks of rage or violence. See case below for additional details regarding the safety of benzodiazepines in the treatment of anxiety associated with PTSD.

Nonbenzodiazepines are also frequently used for the treatment of PTSD-related insomnia. They are thought to offer a better side effect profile and not to disrupt the natural sleep architecture. While a recent placebo-controlled, cross-over, randomized, controlled trial with eszopiclone demonstrated improved sleep quality and decreased sleep latency, the small sample size (N = 24) and 3-week observation period make applying the results very difficult. Additionally, recent warnings regarding these medications causing abnormal thinking and behavior changes, decreased inhibitions, and potential visual and auditory hallucinations suggest that these medications should be used as last-line treatment options for PTSD-related insomnia based on the small amount of data available.

Other options for sleep could include trazodone or mirtazapine. Although trazodone does provide a safer alternative to the use of benzodiazepines and nonbenzodiazepines, only very low-level evidence in survey, open-label, and clinical observation data support its use in PTSD-related insomnia. In a recent randomized controlled trial evaluating augmentation of sertraline with mirtazapine versus sertraline monotherapy, the combination offered no advantage in self-reported sleep disruption.

Severe sleep deprivation warrants the immediate use of medication to prevent harm, while other sleep disorders would benefit from psychotherapy first. The patient in case 2 would benefit from cognitive behavioral therapy for insomnia. The use of sleep medications should be limited to a short duration, although at times, longer medication use may be warranted in PTSD. This patient may benefit from a trial of prazosin as other sleep medications (i.e., nonbenzodiazapine hypnotics and benzodiazepines) can intensify nightmares. Prior to initiation of prazosin, clinical judgement must be used as some patients may respond while others may demonstrate no benefit. Adverse effects (e.g., hypotension) and additive drug-drug interactions should be considered prior to initiating prazosin. When initiating prazosin, the patient should be started on 1 to 2 mg/d at bedtime with an increase of 1 mg every 2 weeks. Mean doses in clinical trials ranged from 2 to 13 mg/d. While once daily dosing at bedtime is frequently used, several trials used twice daily dosing due to the short half-life of prazosin. Other sleep medications, including atypical antipsychotics, benzodiazepines, and nonbenzodiazepines should be avoided and only used as last-line treatment options.

Case 3

A 25-year-old patient being treated for PTSD from a previous sexual assault describes severe anxiety prior to TFP appointments and at bedtime. The patient notes being very anxious and endorses symptoms of a panic attack including shortness of breath, sweating, and feelings of impending death. These attacks typically last 10 to 15 minutes and the patient has only found relief from clonazepam prescribed by an emergency department physician. The patient asks for a continued prescription as it is the only thing that helps. Current medications include fluoxetine 20 mg daily for the past 6 weeks. Past medications include sertraline 150 mg (discontinued because of nausea) and trazodone 150 mg for sleep (did not find this effective).

All treatment guidelines currently recommend against the use of benzodiazepines in the treatment of PTSD because of the lack of evidence for effectiveness and the risks associated with their use; nevertheless, 30% to 74% of patients with PTSD still receive prescriptions for them. Benzodiazepines have been used as a primary or “as needed” agent for the treatment of PTSD anxiety despite the lack of efficacy in randomized controlled trials. There was no significant differences between placebo and alprazolam on the Hamilton Rating Scale for Anxiety, or placebo and clonazepam using sleep diaries in 2 small studies. Use of alprazolam 30 minutes prior to virtual reality exposure sessions demonstrated a reduction in the efficacy of exposure therapy and was associated with more severe PTSD symptoms at 3-month follow-up.

Withdrawal symptoms, tolerance, and dependence can make it difficult to discontinue benzodiazepines. Benzodiazepines are also relatively contraindicated in patients with a history of traumatic brain injury, sleep apnea, chronic obstructive pulmonary disease, or high rates of comorbid alcohol misuse and substance use disorder. Additionally, preclinical data concluded that benzodiazepines could interfere with the extinction of fear conditioning and/or potentiate the acquisition of fear response and worsen recovery from trauma.
The patient in case 3 should be educated about the risks of continued use of benzodiazepines and alternative recommendations should be made regarding other options to help control the anxiety the patient is experiencing. Additional psychotherapy should be offered to the patient as well as maximizing the dose of the antidepressant. As needed medications, such as hydroxyzine, may be beneficial for as needed treatment of anxiety.

**Conclusion**

There are numerous studies with varying degrees of rigor evaluating pharmacotherapy options for PTSD. While guideline authors provide many differing options, SSRIs and SNRIs remain first-line pharmacotherapeutic treatment options for PTSD. Although specific antidepressants may demonstrate greater published efficacy, any antidepressant could be considered with proper monitoring. Atypical antipsychotics lack robust studies demonstrating evidence and have more potentially severe adverse effects, making them last-line treatment options. Mood stabilizers are limited to treatment of comorbid illness because of their lack of data. While many patients continue to receive benzodiazepines for both PTSD-related anxiety and sleep disorders associated with PTSD, they should be avoided. Prazosin can be recommended for those with PTSD-associated nightmares, with proper education regarding its efficacy and blood pressure monitoring. Trauma-focused therapies and other psychotherapies should continue to be recommended first-line in all patients with a diagnosis of PTSD; medications should be used in cases when TFPs are unavailable or unsuccessful, a patient requests medication, or a specific indication compels a medication.

**References**

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.
2. Ursano RJ, Kessler RC, Stein MB, Naifeh JA, Aliaga PA, Fullerton CS, et al. Risk factors, methods, and timing of suicide attempts among U.S. army soldiers. JAMA Psychiatry. 2016;73(7):742-9. DOI: 10.1001/jamapsychiatry.2016.0600. PubMed PMID: 27224848; PubMed Central PMCID: PMC4937827.
3. Smith SM, Goldstein RB, Grant BF. The association between post-traumatic stress disorder and lifetime DSM-5 psychiatric disorders among veterans: data from the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). J Psychiatr Res. 2016;78:16-22. DOI: 10.1016/j.jpsychires.2016.06.022. PubMed PMID: 27455424; PubMed Central PMCID: PMC5026976.
4. Pietrzak RH, Goldstein RB, Southwick SM, Grant BF. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. J Anxiety Disord. 2011;25(3):456-65. DOI: 10.1016/j.janxdis.2010.11.010. PubMed PMID: 21168991; PubMed Central PMCID: PMC3051041.
5. Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1317-28. DOI: 10.1007/s00127-016-1208-5. PubMed PMID: 27106853; PubMed Central PMCID: PMC4980174.
6. Ramchand R, Rudavsky R, Grant S, Tanielian T, Jaycox L. Prevalence of, risk factors for, and consequences of posttraumatic stress disorder and other mental health problems in military populations deployed to Iraq and Afghanistan. Curr Psychiatry Rep. 2015;17(5):37. DOI: 10.1007/s11920-015-0575-z. PubMed PMID: 25876142.
7. American Psychiatric Association. Practice guideline for the treatment of patient with acute stress disorder and posttraumatic stress disorder. Arlington (VA): American Psychiatric Association; 2004.
8. American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder: guideline watch. Arlington (VA): American Psychiatric Association; 2009.
9. Baldwin DS, Anderson IM, Nutt DJ, Alligulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(4):403-39. DOI: 10.1177/0269881114525574. PubMed PMID: 2473617.
10. Australian Centre for Posttraumatic Mental Health. Australian guidelines for the treatment of acute stress disorder and posttraumatic stress disorder. Melbourne, Victoria: Australian Centre for Posttraumatic Mental Health; 2013.
11. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:51. DOI: 10.1186/1471-244X-14-S1-51. PubMed PMID: 25081580; PubMed Central PMCID: PMC4120194.
12. Veterans Health Administration, Department of Defense. VA/DoD clinical practice guideline for the management of posttraumatic stress. Washington: Veterans Health Administration, Department of Defense; 2017.
13. National Institute for Health and Care Excellence. Post-traumatic stress disorder (NICE Quality Standard NG16) [Internet]. c2018 [cited 2019 Sep 9]. Available from: https://www.nice.org.uk/guidance/ng116/evidence.
14. Hoffman V, Middleton JC, Feltner C, Gaynes BN, Weber RP, Bann C, et al. Psychological and pharmacological treatments for adults with posttraumatic stress disorder: a systematic review update. Comparative Effectiveness Review No. 207. Rockville (MD): Agency for Healthcare Research and Quality; 2018.
15. American Psychological Association, Guideline Development Panel for the Treatment of PTSD in Adults. Clinical practice guideline for the treatment of Posttraumatic Stress Disorder (PTSD) in adults [Internet]. c2017 [updated 2019 Sep 9; cited 2019 Feb 11]. Available from: https://www.apa.org/ptsd-guidelines/.
16. Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33(9):792-806. DOI: 10.1002/da.22521. PubMed PMID: 27126398.
17. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttrau-
mastic stress disorder. J Clin Psychiatry. 2013;74(6):654-50. DOI: 10.4088/JCP.12r08225. PubMed PMID: 23842024.

18. Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. Psychiatr Serv. 2008; 59(10):1284-90. DOI: 10.1176/appi.ps.59.10.1184. PubMed PMID: 18832505.

19. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Psychotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2015;206(2):93-100. DOI: 10.1192/bjp.bp.114.145551. PubMed PMID: 25644881.

20. Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48(22):1975-84. DOI: 10.1017/S003329171700349X. PubMed PMID: 29256416.

23. McRae AL, Brady KT, Mellman TA, Sonne SC, Killeen TK, Timmerman MA, et al. Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety. 2004;19(3):190-6. DOI: 10.1002/da.20008. PubMed PMID: 15139422.

25. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL Jr. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179(6):366-70. DOI: 10.1097/00005053-199106000-00011. PubMed PMID: 2051352.

26. Villareal G, Hamner MB, Cañive JM, Robert S, Calais LA, Durklaski V, et al. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. Am J Psychiatry. 2016;173(12):1205-12. DOI: 10.1176/appi.ajp.2016.15070967. PubMed PMID: 27418378.

28. Krystal JH, Rosenheck RA, Cramer JA, Vescichio JC, Jones KM, Vertrees JE, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2013;309(6):507-17. DOI: 10.1056/NEJMoa1305798. PubMed PMID: 23441272.

30. Rasmussen KE, Faerch AM, Thinggaard M, Fenger M, Fenger M, Høgholt A, et al. A guide to guidelines for the treatment of PTSD and related conditions. J Trauma Stress. 2010;23(5):537-52. DOI: 10.1002/jts.20565. PubMed PMID: 20839310.

32. Lamictal (lamotrigine) [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2015.

33. Depakote (divalproex sodium) [package insert]. North Chicago: Abbott Laboratories; 1998.

34. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine; 2014.

35. Forbes D, Creamer M, Bisson JJ, Cohen JA, Crow BE, Foa EB, et al. A guide to guidelines for the treatment of PTSD and related conditions. J Trauma Stress. 2010;23(5):537-52. DOI: 10.1002/jts. 20565. PubMed PMID: 20839310.

36. Davis LL, Jewell ME, Ambrose S, Farley J, English B, Bartolucci PA, et al. A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2004;24(3):291-7. DOI: 10.1097/01.jcp.0000125685.82219.1a. PubMed PMID: 15118483.

38. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(6):371-3. DOI: 10.1176/appi.ajp.160.2.371. PubMed PMID: 12562588.

40. Raskind MA, Peskind ER, Hoffman DJ, Hart KL, Holmes HA, Warren D, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928-34. DOI: 10.1016/j.biopsych.2006.06.032. PubMed PMID: 17069688.

41. Forman SD, et al. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans. J Psychosom Res. 2012;73(2):89-96. DOI: 10.1016/j.jpsychores.2011.11.010. PubMed PMID: 22284148.

42. Raskind MA, Peterson K, Williams T, Hoffman DJ, Hart, K, Holmes H, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013;170(9):1003-10. DOI: 10.1176/appi.ajp.2013.12081133. PubMed PMID: 23846759.

43. Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507-17. DOI: 10.1056/NEJMoa1507598. PubMed PMID: 29441272.

44. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross DJ, et al. A trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507-17. DOI: 10.1056/NEJMoa1507598. PubMed PMID: 29441272.

45. Cotter MA, Laskar RE, McDonald J, Smith LJ, Gullion CM, et al. Prazosin as a treatment for sleep-related symptoms in juvenile trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008;63(6):629-32. DOI: 10.1016/j.biopsych.2007.07.001. PubMed PMID: 17886855.

46. Ahmadpanah M, Sabzeiee P, Hosseini SM, Torabian S, Haghighi M, Jahangard L, et al. Comparing the effect of prazosin and metoprolol on sleep quality in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2014;69(4):235-42. DOI: 10.1159/000352243. PubMed PMID: 24993821.

47. Boynton L, Bentley J, Strachan E, Barbato A, Raskind M. Preliminary findings concerning the use of prazosin for the treatment of posttraumatic nightmares in a refugee population. J Psychiatr Pract. 2009;15(6):454-9. DOI: 10.1097/01.pra. 00004627.63210.92. PubMed PMID: 19934720.
47. Daly CM, Doyle ME, Radkind M, Raskind E, Daniels C. Clinical case series: the use of prazosin for combat-related recurrent nightmares among operation Iraqi freedom combat veterans. Mil Med. 2005;170(6):531-5. DOI: 10.7205/MILMED.170.6.531. PubMed PMID: 16001603.

48. Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol. 2003;16(3):165-71. DOI: 10.1177/0891988703256050. PubMed PMID: 12967066.

49. Raskind MA, Dobie DJ, Kanter ED, Thompson CE, Peskind ER. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry. 2000;61(2):129-33. DOI: 10.4088/JCP.v61n0208. PubMed PMID: 10732660.

50. Taylor F, Raskind MA. The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol. 2002;22(1):82-5. DOI: 10.1097/00004714-200202000-00013. PubMed PMID: 11799347.

51. Jakovljević M, Sagud M, Mihaljević-Peles A. Olanzapine in the treatment-resistant, combat-related PTSD—a series of case reports. Acta Psychiatr Scand. 2003;107(5):394-6. DOI: 10.1034/j.1600-0447.2003.00065.x. PubMed PMID: 12752037.

52. David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety. 2006;21(2):89-92. DOI: 10.1002/da.20187. PubMed PMID: 16856593.

53. Stanovic JK, James KA, VanDeveer CA. The effectiveness of risperidone on acute stress symptoms in adult burn patients: a preliminary retrospective pilot study. J Burn Care Rehabil. 2003;24(3):210-3. DOI: 10.1097/00004630-200305000-00005. PubMed PMID: 11403240.

54. Lambert MT. Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans. Int Clin Psychopharmacol. 2006;21(3):185-7. DOI: 10.1097/01.yic.0000185021.48279.00. PubMed PMID: 16528142.

55. Nappi CM, Drummond SPA, Hall JM. Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. Neuropharmacology. 2012;63(5):876-85. DOI: 10.1016/j.neuropharm.2011.02.029. PubMed PMID: 21396445.

56. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990;51(6):236-8. PubMed PMID: 2189869.

57. Cates ME, Bishop MH, Davis LL, Lowe JS, Woolley TW. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother. 2004;38(9):1395-9. DOI: 10.1345/aph.1e043. PubMed PMID: 15252193.

58. van der Bijl P, Roelofse JA. Disinhibitory reactions to benzodiazepines: a review. J Oral Maxillofac Surg. 1993;49(5):539-23. DOI: 10.0167/1278-2391(93)90180-t. PubMed PMID: 2039899.

59. Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010;24(11):1601-12. DOI: 10.1177/0269881109106927. PubMed PMID: 19942638.

60. Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(7):892-7. DOI: 10.4088/JCP.09m05799y. PubMed PMID: 21367352.

61. Lipinska G, Baldwin DS, Thomas KGF. Pharmacology for sleep disturbance in PTSD. Hum Psychopharmacol. 2016;31(2):156-63. DOI: 10.1002/hup.2521. PubMed PMID: 26858810.

62. Schneier FR, Campeas R, Carcamo J, Glass A, Lewis-Fernandez R, Neria Y, et al. Combined mirtazapine and SSRI treatment of PTSD: a placebo-controlled trial. Depress Anxiety. 2015;32(8):570-9. DOI: 10.1002/da.22384. PubMed PMID: 26115513. PubMed Central PMCID: PMC451568.

63. Ambien (zolpidem) [package insert]. Bridgewater (NJ): Sanofi-Aventis; 2008.

64. Lund BC, Bernardy NC, Alexander B, Friedman MJ. Declining benzodiazepine use in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):292-6. DOI: 10.4088/JCP.10m06775. PubMed PMID: 22152399.

65. Rothbaum BO, Price M, Jovanovic T, Norholm SD, Gerardi M, Dunlop B, et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry. 2011;168(6):640-8. DOI: 10.1176/appi.ajp.2011.11021625. PubMed PMID: 218743802.

66. Higgitt A, Fonagy P, Lader M. The natural history of tolerance to the benzodiazepines. Psychol Med Monogr Suppl. 1988;13:1-55. DOI: 10.1017/S0264180100000412. PubMed PMID:2908516.

67. Sellers EM. Clinical Pharmacology and therapeutics of benzodiazepines. Can Med Assoc J. 1990;142(10):1189-95. DOI: 10.1136/jcp.1990.142.10.1189. PubMed PMID: 22152399.

68. Matar MA, Zohar J, Kaplan Z, Cohen H. Alprazolam treatment immediately after stress exposure interferes with the normal HPA-stress response and increases vulnerability to subsequent stress in an animal model of PTSD. Eur Neuropsychopharmacol. 2009;19(4):283-9. DOI: 10.1016/j.euroneuro.2008.12.004. PubMed PMID: 19167197.

69. Hebert MA, Potegal M, Moore T, Evenson AR, Meyerhoff JL. Diazepam enhances conditioned defeat in hamsters (Mesocricetus auratus). Pharmacol Biochem Behav. 1996;55(3):405-13. DOI: 10.1016/S0091-3057(96)00110-4.